Predictors of Diffuse In-Stent Restenosis, a Retrospective Analysis in a Subset of Egyptian Population

Ahmed Mahmoud El Amrawy; Mohamed Ibrahim Loutfi; Ahmed Mokhtar Abd El Azeem

doi:10.30701/ijc.1656

Ahmed Mahmoud El Amrawy Cardiology Department, Faculty of Medicine, Alexandria University, Egypt
Mohamed Ibrahim Loutfi Cardiology Department, Faculty of Medicine, Alexandria University, Egypt
Ahmed Mokhtar Abd El Azeem Cardiology Department, Faculty of Medicine, Alexandria University, Egypt

Keywords: Diffuse in-stent restenosis, stent length, predictors of in-stent restenosis

Abstract

Background: Despite the fact that DES implantation has decreased theincidence of ISR dramatically, it is not negligible. Diffuse ISR is associated withpoor outcomes. Most of the data regarding ISR are obtained from studiesincluding BMS stents.

Methods: A total of 263 ISR patients were treated at two tertiary carehospitals from September 2017 through December 2022. 40 patients wereexcluded because the previous angiography and procedure details were notavailable, IVUS data were available for only 30 patients and the patients werenot included in the analysis, so only 193 ISR patients were included in theanalysis. We compared different clinical and procedural risk factors betweendiffuse and focal patterns of ISR following DES implantations.

Results: A total of 193 ISR lesions were included in the analysis, distributedas 53.4% diffuse pattern and 46.6% focal pattern. In the multivariate analysis,only increased stent length [OR 1.270 (1.157 – 1.394) 95%CI, P<0.001],lower LVEF [OR 0.903, (0.860 – 0.949) 95%CI, P<0.001], occurrence ofprocedural complications [OR 15.584 (2.075 – 117.044) 95%CI, P=0.008],smoking [OR 3.182, (1.071 – 9.451) 95%CI, P=0.037] and older age [OR1.086, (1.014 – 1.163) 95%CI, P=0.019] were independent risk factors ofdiffuse ISR. DM was not associated with diffuse ISR in the multivariate analysis.

Conclusions: Increased age, smoking, reduced left ventricular ejectionfraction, occurrence of procedural complications and increased stent lengthare independent predictors of diffuse ISR. Diabetes mellitus was not found tobe independently associated with a diffuse pattern of ISR.

Downloads

Download data is not yet available.

References

1. Tsao CW, Aday AW, Almarzooq ZI, Beaton AZ, Bittencourt MS, Boehme AK, et al. Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association. Circulation. 2022;145(8):e153–e639.
2. Sanati H. Pre-procedural serum lipid profile and post-procedural myocardial injury. Res Cardiovasc Med. 2013;2(4):174–5.
3. Bhatt DL. Percutaneous coronary intervention in 2018. JAMA. 2018;319(20):2127–8.
4. Grines CL, Harjai KJ, Schreiber TL. Percutaneous coronary intervention: 2015 in review. J Interv Cardiol. 2016;29(1):11–26.
5. Mehran R, Dangas G, Abizaid AS, Mintz GS, Lansky AJ, Satler LF,et al. Angiographic patterns of in-stent restenosis: classification and implications for long-term outcome. Circulation.1999;100(18):1872–8.
6. Buccheri D, Piraino D, Andolina G, Cortese B. Understanding and managing in-stent restenosis: a review of clinical data, from pathogenesis to treatment. J Thorac Dis. 2016;8(10):E1150–62.
7. Zhang DM, Chen S. In-stent restenosis and a drug-coated balloon: insights from a clinical therapeutic strategy on coronary artery diseases. Cardiol Res Pract. 2020; 2020:8104939.
8. Omar A, Pendyala LK, Ormiston JA, Waksman R. Review: Stent fracture in the drug-eluting stent era. Cardiovasc Revasc Med. 2016 Sep;17(6):404-11
9. Byrne RA, Joner M, Tada T, Kastrati A. Restenosis in bare metal and drug-eluting stents: distinct mechanistic insights from histopathology and optical intravascular imaging. Minerva Cardioangiol. 2012;60(5):473–89.
10. Saia F, Lemos PA, Arampatizis CA, Hoye A, Degertekin M, Tanabe K, et al: Routine sirolimus eluting stent implantation for unselected in-stent restenosis: insights from the rapamycin eluting stent evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Heart 90: 1183-1188, 2004.
11. Asamasu-Sato S, Mita M, Ogawa R, Isaka M, Saito M. Analysis of clinical factors that influence re-stenosis after percutaneous coronary stenting. Yakugaku zasshi J Pharm Soc Jpn. 2007;127(8):1309–15.
12. Paramasivam G, Devasia T, Jayaram A, Rao MS, Vijayvergiya R, et al. In-stent restenosis of drug-eluting stents in patients with diabetes mellitus: clinical presentation, angiographic features, and outcomes. Anatol J Cardiol. 2020;23(1):28–34.
13. Zeng, M., Yan, X. & Wu, W. Risk factors for revascularization and in-stent restenosis in patients with triple-vessel disease after second-generation drug-eluting stent implantation: a retrospective analysis. BMC Cardiovasc Disord 21, 446 (2021). https://doi.org/10.1186/s12872-021-02259-0
14. Jang JS, Buchanan DM, Gosch KL, Jones PG, Sharma PK, Shafiq A, et al. Association of smoking status with health-related outcomes after percutaneous coronary intervention. Circ Cardiovasc Interv. 2015;8(5):e002226.
15. Rittersma SZ, de Winter RJ, Koch KT, Schotborgh CE, Bax M, Heyde GS, et al. Preprocedural C-reactive protein is not associated with angiographic restenosis or target lesion revascularization after coronary artery stent placement. Clin Chem. 2004;50(9):1589–96.
16. Cohen DJ, Doucet M, Cutlip DE, Ho KK, Popma JJ, Kuntz RE. Impact of smoking on clinical and angiographic restenosis after percutaneous coronary intervention: another smoker’s paradox? Circulation. 2001;104(7):773–8.
17. Zhang YJ, Iqbal J, van Klaveren D, Campos CM, Holmes DR, Kappetein AP, et al. Smoking is associated with adverse clinical outcomes in patients undergoing revascularization with PCI or CABG: the SYNTAX trial at 5-year follow-up. J Am Coll Cardiol. 2015;65(11):1107–15.
18. Li M, Hou J, Gu X, Weng R, Zhong Z, Liu S. Incidence and risk factors of in-stent
restenosis after percutaneous coronary intervention in patients from southern China. European Journal of Medical Research (2022) 27:12.
19. Hong MK, Mintz GS, Lee CW, Park DW, Choi BR, Park KH, et al. Intravascular ultrasound predictors of angiographic restenosis after sirolimus-eluting stent implantation. Eur Heart J. 2006;27(11):1305–10.
20. Goldberg SL, Loussararian A, De Gregorio J, Di Mario C, Albiero R, Colombo A. Predictors of diffuse and aggressive intra-stent restenosis. J Am Coll Cardiol. 2001 Mar 15;37(4):1019-25.
21. Kedhi E, Généreux P, Palmerini T, McAndrew TC, Parise H, Mehran R, et al. Impact of coronary lesion complexity on drug-eluting stent outcomes in patients with and without diabetes mellitus: analysis from 18 pooled randomized trials. J Am Coll Cardiol. 2014;63(20):2111–8.
22. Hwang JK, Lee SH, Song YB, Ahn J, Carriere K, Jang MJ, et al. Glycemic control status after percutaneous coronary intervention and long-term clinical outcomes in patients with type 2 diabetes mellitus. Circ Cardiovasc Interv. 2017;10(4):e004157.
23. Marfella R, Sasso FC, Cacciapuoti F, Portoghese M, Rizzo MR, Siniscalchi M, et al. Tight glycemic control may increase regenerative potential of myocardium during acute infarction. J Clin Endocrinol Metab. 2012;97(3):933–42.
24. Sasso FC, Rinaldi L, Lascar N, Marrone A, Pafundi PC, Adinolfi LE, et al. Role of tight glycemic control during acute coronary syndrome on CV outcome in type 2 diabetes. J Diabetes Res. 2018;2018:3106056.
25. Park CB, Park HK. Predictors of diffuse-type in-stent restenosis
following drug-eluting stent implantation. Experimental and therapeutic medicine. 2013:(5)1486-90.